Cargando…
1409. Evaluation of Alternative Piperacillin–tazobactam Dosing Strategies Against ESBL-Producing Enterobacteriaceae Using a Hollowfiber Infection Model
BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae exhibit variable response to treatment with piperacillin–tazobactam. Current clinical practice with piperacillin–tazobactam involves dosing the components simultaneously at a fixed ratio of 8:1 piperacillin to tazobactam....
Autores principales: | Abodakpi, Henrietta, Chang, Kai-Tai, Sánchez-Díaz, Ana Maria, Cantón, Rafael, Tam, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254524/ http://dx.doi.org/10.1093/ofid/ofy210.1240 |
Ejemplares similares
-
1410. Novel Framework to Compare the Effectiveness of Tazobactam, Relebactam and Avibactam Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
por: Abodakpi, Henrietta, et al.
Publicado: (2018) -
2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018) -
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017) -
260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014) -
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)